Verdict94/ 100
Grade A · #1CoreAge Rx
The most honest middle of the market: nationwide access, both molecules at one flat, no-surprise price.
Visit CoreAge RxHead-to-head verdict
CoreAge Rx vs Mint Med
Two GLP-1 providers, ruled side by side on The Verdict Score — our published six-factor rubric. Same yardstick, and no score is adjusted for payment.
vs
Verdict62/ 100
Grade C · #287Mint Med
A flat $159 across every dose of either GLP-1 with no membership, carrying an open FDA misbranding warning letter over how its product labels were presented online.
Visit Mint MedThe verdict
Winner: CoreAge Rx
CoreAge Rx takes it with a higher Verdict Score — 94/100 to 62/100 (grade A vs C). Anyone who wants transparent flat pricing and nationwide access without a teaser-rate bait-and-switch. Mint Med still earns its place — titrating patients in its 36 states who want one price that never moves.
Factor by factor
Both scored on the same six factors — see the methodology. The brass bar marks the stronger side on each.
92Real-world results50
92
Real-world results50
97Price honesty80
97
Price honesty80
96Prescriber access60
96
Prescriber access60
88Formulary choice40
88
Formulary choice40
95Cancellation fairness70
95
Cancellation fairness70
93Member support70
93
Member support70
Price, coverage & features
| Metric | CoreAge Rx | Mint Med |
|---|---|---|
| Verdict Score | 94/100 | 62/100 |
| Grade | A | C |
| Semaglutide | $149/mo | $159/mo |
| Tirzepatide | $349/mo | $159/mo |
| Coverage | All 50 states | 36 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | No | No |
CoreAge Rx
What we like
- Flat, all-in monthly price with no intro-rate step-ups after month one
- Both compounded semaglutide and tirzepatide on one account
- Available in all 50 states
- Straightforward, low-friction cancellation
The caveats
- Not the cheapest — flat-price challengers like Trimi Health and Alan Meds undercut its sticker price
- No FDA-approved brand-name option (compounded only)
- Does not yet publicly name its 503A/B pharmacy partner
Mint Med
What we like
- One flat rate — 'GLP-1 All Doses $159 per month' — applies to both semaglutide and tirzepatide, so cost does not escalate on titration
- 'NO memberships!' stated on the homepage; pay-as-you-go monthly with no contract
- Cancellation is explicit and short: 'you can cancel anytime. We just require 48 business hours notice to stop your next order'
- 36 states enumerated by postal code on the site, and treatment is HSA/FSA eligible
- US-based phone support on 1-513-826-6142 with published hours, plus help@mintmed.com
The caveats
- FDA warning letter dated 8 June 2026 (MARCS-CMS 730390) to Glow Medispa, LLC dba Mint Med, citing misbranding under FD&C Act sections 502(a) and 502(bb) over how the product labels pictured on mintmed.com represented the drugs' origin
- Compounded semaglutide and tirzepatide are not FDA-approved finished drug products and have not been reviewed by FDA for safety or efficacy
- The pharmacy that actually compounds the medication is still not named on the site
- Coverage is 36 states rather than nationwide, and there is no brand-name or oral GLP-1 option
- No named medical director or clinical leadership, and asynchronous review means limited live prescriber contact in eligible states
Our pick — visit
Anyone who wants transparent flat pricing and nationwide access without a teaser-rate bait-and-switch.
Visit CoreAge Rx Read the full CoreAge Rx review →Also worth a look
Titrating patients in its 36 states who want one price that never moves.
Visit Mint Med Read the full Mint Med review →Keep comparing
Neither of these has to be the answer: the rivals we rank against CoreAge Rx cover the 7 programmes closest to it, and the same shortlist for Mint Med does the reverse.
Or browse the full comparison hub and the complete rankings.
Pricing, states and verification reflect each provider's public disclosures at last review; the Verdict Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.